Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib and Toripalimab in Metastatic Pancreatic Ductal Adenocarcinoma
NCT07445295Phase 3Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of chiauranib in pancreatic adenocarcinoma (PDAC), sponsored by Akeso, Inc.. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
chiauranib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07445295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445295.